GSP Crop Science deploys Rs 238.219 crore of IPO proceeds

GSP Crop Science Limited reported that it had used Rs 238.219 crore of its Rs 240 crore fresh initial public offer proceeds by September 30, 2026, with Rs 170 crore fully deployed to repay or prepay borrowings and Rs 17.81 lakh remaining from the issue-expense allocation. The company reported no deviation from the prospectus objects.

How did GSP Crop Science use its IPO proceeds?

GSP Crop Science used Rs 238.219 crore of the Rs 240 crore raised through its fresh issue as of September 30, 2026. Repayment or prepayment of certain outstanding borrowings was the largest stated object, receiving Rs 170 crore, or more than seven-tenths of the fresh-issue proceeds, and the company reported that this allocation was fully utilised.

The other two objects were general corporate purposes and issue expenses. GSP Crop Science had fully used the Rs 50.317 crore assigned to general corporate purposes, while it had used Rs 17.902 crore of the Rs 19.683 crore allocated to issue expenses. The unutilised balance was Rs 17.81 lakh, which was the only unutilised amount in the statement.

The source reports the issue-expense balance as Rs 17.81 lakh, rather than Rs 0.1781 crore. It identifies auditor’s fees, commissions, brokerage and other issue-related expenses as the uses of money spent under that allocation. It does not separately state which future expense, if any, will use the remaining balance.

Did GSP Crop Science deviate from its IPO prospectus?

No, GSP Crop Science reported no deviation or variation in the utilisation of its fresh IPO proceeds for the quarter ended September 30, 2026. Its disclosure records no modified object, no modified allocation and zero deviation or variation for each of the three stated purposes of the Rs 240 crore fresh issue.

The Audit Committee reviewed the position and noted that there was no deviation or variation in using IPO proceeds from the objects stated in the prospectus. The company also marked shareholder approval as not applicable, because the filing reports no change in either the stated objects or the terms of a contract connected with the fund raising.

The statement defines deviation or variation to include a departure from the purpose for which funds were raised, a difference between actual use and an amount originally disclosed, or a change in terms of a contract referred to in the prospectus or another fund-raising document. GSP Crop Science did not report any of these outcomes as of September 30, 2026.

Which IPO objects were fully used by June 30, 2026?

GSP Crop Science had fully used both the Rs 170 crore borrowing-repayment allocation and the Rs 50.317 crore general-corporate-purpose allocation by June 30, 2026. The remarks in the utilisation statement specifically state that proceeds for both objects were fully utilised as of that date, three months before the September 30 reporting date.

That means Rs 220.317 crore, across the two objects, had no remaining balance by June 30, 2026. The borrowing allocation was more than three times the general-corporate-purpose allocation, at Rs 170 crore compared with Rs 50.317 crore, making debt repayment or prepayment the principal use of the fresh issue.

The September 30 disclosure continues to show zero unutilised funds for these two objects. By contrast, issue expenses had an original allocation of Rs 19.683 crore and showed Rs 17.902 crore utilised at September 30, leaving Rs 17.81 lakh. The filing does not provide an issue-expense utilisation figure specifically for June 30.

What changed between June and September 2026?

The filing shows no change in the reported status of the Rs 170 crore borrowing allocation or the Rs 50.317 crore general-corporate-purpose allocation between June 30 and September 30, 2026. Both were already fully utilised as of June 30, and both remained fully utilised in the quarter-end statement for September 30.

For issue expenses, the company reported Rs 17.902 crore utilised by September 30 against the Rs 19.683 crore allocation. However, because the disclosure does not state the amount used for issue expenses at June 30, it does not support a calculation of spending on that object during the July-to-September quarter.

The difference in completion status is clear from the remaining balances. Borrowing repayment and general corporate purposes each had zero balance at September 30, while issue expenses retained Rs 17.81 lakh. GSP Crop Science nevertheless reported zero deviation for all three objects, meaning the residual balance was not classified as a change in purpose or allocation.

When did GSP Crop Science raise the funds and who monitors them?

GSP Crop Science raised the funds through a public issue with March 20, 2026 as the allotment date. The public issue comprised a Rs 240 crore fresh issue and a Rs 160 crore offer for sale, while the proceeds-utilisation table tracks the Rs 240 crore fresh issue allocated to the company’s stated objects.

CRISIL Ratings Limited is named as the monitoring agency in the September 30, 2026 statement. The filing identifies monitoring agency coverage as applicable, and names CRISIL Ratings Limited alongside the company’s report on deviation or variation in utilisation of public-issue funds.

The offer for sale is listed separately from the fresh issue at Rs 160 crore. GSP Crop Science’s utilisation table does not assign company-use objects to the offer for sale, whereas it breaks down the fresh-issue amount into Rs 170 crore for borrowings, Rs 50.317 crore for general corporate purposes and Rs 19.683 crore for issue expenses.

Conclusion

GSP Crop Science’s September 30, 2026 disclosure shows that Rs 238.219 crore of its Rs 240 crore fresh IPO proceeds had been used, led by the Rs 170 crore allocation for repayment or prepayment of outstanding borrowings. The company reported no deviation, no modified object and no modified allocation, while the Audit Committee also noted no variation from the prospectus objectives.

The next disclosed point to watch is the Rs 17.81 lakh remaining in the issue-expense allocation. GSP Crop Science has not disclosed a timetable or detailed future use for that balance, so a subsequent utilisation statement would show whether the Rs 19.683 crore issue-expense allocation has been fully used and whether the company continues to report no deviation.